Open Access Highly Accessed Open Badges Research article

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

Idrian García-García1*, Carlos A González-Delgado2, Carmen M Valenzuela-Silva1, Alina Díaz-Machado2, Marisol Cruz-Díaz1, Hugo Nodarse-Cuní1, Orlando Pérez-Pérez2, Cimara H Bermúdez-Badell1, Joel Ferrero-Bibilonia3, Rolando Páez-Meireles4, Iraldo Bello-Rivero1, Fidel R Castro-Odio4, Pedro A López-Saura1 and for the FarmaPEG Study Group

Author Affiliations

1 Clinical Trials Division, Center for Biological Research, Havana, Cuba

2 National Center for Toxicology, "Carlos J. Finlay" University Hospital, Havana, Cuba

3 Quality Control Direction, Center for Genetic Engineering and Biotechnology, Havana, Cuba

4 Development Direction, Center for Genetic Engineering and Biotechnology, Havana, Cuba

For all author emails, please log on.

BMC Pharmacology 2010, 10:15  doi:10.1186/1471-2210-10-15

Published: 23 November 2010



Interferon (IFN) alpha conjugation to polyethylene glycol (PEG) results in a better pharmacokinetic profile and efficacy. The aim of this study was to compare the pharmacokinetic, pharmacodynamic and safety properties of a new, locally developed, 40-kDa PEG-IFN alpha-2b preparation with a reference, commercially available PEG-IFN alpha-2a in healthy male volunteers.


A randomized, crossover, double-blind study with a 3-weeks washout period, was done. A single 180 micrograms PEG-IFN alpha-2 dose was administered subcutaneously in both groups. Sixteen apparently healthy male subjects were included. Serum PEG-IFN concentration was measured during 336 hours by an enzyme immunoassay (EIA). Other clinical and laboratory variables were used as pharmacodynamic and safety criteria.


The pharmacokinetic comparison by EIA yielded a high similitude between the formulations. In spite of a high subject variability, the parameters' mean were very close (in all cases p > 0.05): AUC: 53623 vs. 44311 pg.h/mL; Cmax: 333 vs. 271 pg/mL; Tmax: 54 vs. 55 h; half-life (t1/2): 72.4 vs. 64.8 h; terminal elimination rate (lambda): 0.011 vs. 0.014 h-1; mean residence time (MRT): 135 vs. 123 h for reference and study preparations, respectively. There were no significant differences with respect to the pharmacodynamic variables either: serum neopterin and beta-2 microglobulin levels, stimulation of 2'5' oligoadenylate synthetase expression, and serum IFN antiviral activity. A strong Spearman's rank order correlation (p < 0.01) between the pharmacokinetic and pharmacodynamic concentration-time curves was observed. Both products caused similar leukocyte counts diminution and had similar safety profiles. The most frequent adverse reactions were leukopenia, fever, thrombocytopenia, transaminases increase and asthenia, mostly mild.


Both formulations are fully comparable from the pharmacokinetic, pharmacodynamic, and safety profiles. Efficacy trials can be carried out to confirm clinical similarity.

Trial registration

Registro Público Cubano de Ensayos Clínicos RPCEC00000039.